Ziihera Injection, Powder, Lyophilized, For Solution
Product Images NDC 68727-950

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Ziihera (NDC 68727-950). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jazz Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ziihera Carton (Ziihera Us Carton Label)

Packaging label for ZIIHERA (zanidatamab-hrii) injection, 300 mg per vial, lyophilized powder for intravenous infusion. The label indicates reconstitution with sterile water to a 50 mg/mL concentration. Distributed by Jazz Pharmaceuticals, Inc. The label includes storage instructions and manufacturer details for Jazz Pharmaceuticals Ireland Limited.*

FDA Label Image

Ziihera Vial Label (Ziihera Us Vial Label)

Label for ZIIHERA (zanidatamab-hrii) injection, powder, lyophilized, for solution, 300 mg per vial. The label indicates it is for intravenous infusion only, requires reconstitution and dilution, and is a single-dose vial. The product is manufactured by Jazz Pharmaceuticals Ireland Limited and storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.